Migraine is a type of headache with a throbbing character that begins at childhood, adolescence or early adulthood, often accompanied by symptoms such as nausea, light and sound sensitivity. Depression is the most common psychiatric disorder among migraine patients. Migraine and depression affect many people and have a similar prevalence of about 10 and 15%. If migraine treatment is incomplete, depression may occur as a result of the helplessness. Treatment in migraine is carried out in two stages; acute attack and prophylactic treatment. While analgesics, non-steroidal antiinflammatory drugs, ergot alkaloids and triptans are used in acute attack, drugs such as beta blockers, antiepileptics, antidepressants are used in prophylactic treatment. The success of these drugs in reducing the number and severity of attacks in patients can not be achieved with full success. Therefore, the effects of different antidepressant drug groups are investigated. Selective serotonin reuptake inhibitors (SSRIs), selective serotonin-noradrenaline reuptake inhibitors (SNRIs) and especially tricyclic antidepressants (TCA) are preferred especially with depression, stress, anxiety and sleep disturbance in the prophylactic pharmacological treatment of patients with frequent migraine attacks. In this study we aimed to investigate the effects of antidepressants used in migraine treatment on the severity and duration of migraine.